Controversies in glaucoma: Current medical treatment and drug development

Current Pharmaceutical Design

Volumn 21, Issue 32, 2015, Pages 4673-4681

  Bucolo, Claudio ^a   Platania, Chiara Bianca Maria ^a   Reibaldi, Michele ^a   Bonfiglio, Vincenza ^a   Longo, Antonio ^a   Salomone, Salvatore ^a   Drago, Filippo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Drug development; Glaucoma; Intraocular pressure; IOP lowering drugs

Indexed keywords

ADENOSINE DERIVATIVE; ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANNABINOID RECEPTOR; CARBON MONOXIDE; DOPAMINE RECEPTOR STIMULATING AGENT; HYDROXYSTEROID DEHYDROGENASE 1 INHIBITOR; MELATONIN DERIVATIVE; NITRIC OXIDE; PROSTAGLANDIN DERIVATIVE; RHO KINASE INHIBITOR; SEROTONIN AGONIST; UNCLASSIFIED DRUG; ADRENERGIC RECEPTOR STIMULATING AGENT; CARBONATE DEHYDRATASE INHIBITOR; MIOTIC AGENT; PROSTAGLANDIN;

AQUEOUS HUMOR FORMATION; AQUEOUS HUMOR INFLOW; AQUEOUS HUMOR OUTFLOW; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG THERAPY; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; DRUG EFFECTS; PROCEDURES; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CARBONIC ANHYDRASE INHIBITORS; DRUG DISCOVERY; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MIOTICS; PROSTAGLANDINS; SYMPATHOMIMETICS; TREATMENT OUTCOME;

EID: 84947924261     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150909095553     Document Type: Review

References (100)

1. Kingman S. Glaucoma is second leading cause of blindness globally. In: Organization WH, ed., Bulletin of the World Health Organization 2004.
2. Quigley HA. Open-angle glaucoma. N Engl J Med 1993; 328: 1097-106.
3. Leydhecker W, Akiyama K, Neumann HG. Intraocular pressure in normal human eyes. Klinische Monatsblatter fur Augenheilkunde und fur augenarztliche Fortbildung 1958; 133: 662-70.
4. Hollows FC, Graham PA. Intra-ocular pressure, glaucoma, and glaucoma suspects in a defined population. Br J Ophthalmol 1966; 50: 570-86.
5. Lundberg L, Wettrell K, Linner E. Ocular hypertension. A prospective twenty-year follow-up study. Acta Ophthalmol 1987; 65: 705- 8.
6. Osborne NN, Melena J, Chidlow G, Wood JP. A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma. Br J Ophthalmol 2001; 85: 1252-9.
7. Doucette LP, Rasnitsyn A, Seifi M, Walter MA. The interactions of genes, age, and environment in glaucoma pathogenesis. Surv Ophthalmol 2015; 60: 310-26.
8. Heijl A. Glaucoma treatment: by the highest level of evidence. Lancet 2015; 385: 1264-6.
9. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol 1998; 126: 498-505.
10. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268-79.
11. Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo- controlled trial. Lancet 2015; 385: 1295-304.
12. Platania CB. Implications of dopamine D3 receptor for glaucoma: in-silico and in-vivo studies. Clinical and molecular biomedicine, section of pharmacology. University of Catania 2013.
13. Yamaguchi Y, Watanabe T, Hirakata A, Hida T. Localization and ontogeny of aquaporin-1 and -4 expression in iris and ciliary epithelial cells in rats. Cell Tissue Res 2006; 325: 101-9.
14. Krupin T, Becker B, Podos SM. Topical vanadate lowers intraocular pressure in rabbits. Investig Ophthalmol Visual Sci 1980; 19: 1360-63.
15. Maren TH. The rates of movement of Na+, Cl-, and HCO-3 from plasma to posterior chamber: effect of acetazolamide and relation to the treatment of glaucoma. Investig Ophthalmol 1976; 15: 356- 64.
16. Bill A, Svedbergh B. Scanning electron microscopic studies of the trabecular meshwork and the canal of Schlemm--an attempt to localize the main resistance to outflow of aqueous humor in man. Acta Ophthalmol 1972; 50: 295-320.
17. Ethier CR, Kamm RD, Palaszewski BA, Johnson MC, Richardson TM. Calculations of flow resistance in the juxtacanalicular meshwork. Investig Ophthalmol Visual Sci 1986; 27: 1741-50.
18. Francois J, Victoria-Troncoso V. Corticosteroid glaucoma. Ophthalmologica. Journal international d'ophtalmologie. Int J Ophthalmol Zeitschrift fur Augenheilkunde 1977; 174: 195-209.
19. Johnson DH, Bradley JM, Acott TS. The effect of dexamethasone on glycosaminoglycans of human trabecular meshwork in perfusion organ culture. Investig Ophthalmol Visual Sci 1990; 31: 2568- 71.
20. Barany EH. The mode of action of miotics on outflow resistance. A study of pilocarpine in the vervet monkey Cercopithecus ethiops. Trans Ophthalmol Soc UK 1966; 86: 539-78.
21. Gabelt BT, Kaufman PL. Changes in aqueous humor dynamics with age and glaucoma. Prog Retinal Eye Res 2005; 24: 612-37.
22. Toris CB, Yablonski ME, Wang YL, Camras CB. Aqueous humor dynamics in the aging human eye. Am J Ophthalmol 1999; 127: 407-12.
23. Gabelt BT, Kaufman PL. Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res 1989; 49: 389-402.
24. Yucel YH, Johnston MG, Ly T, et al. Identification of lymphatics in the ciliary body of the human eye: a novel "uveolymphatic" outflow pathway. Exp Eye Res 2009; 89: 810-9.
25. Ruponen M, Urtti A. Undefined role of mucus as a barrier in ocular drug delivery. Eur J Pharm Biopharm. 2015; pii: S0939- 6411(15)00141-1. doi: 10.1016/j.ejpb.2015.02.032.
26. Gipson IK. Distribution of mucins at the ocular surface. Exp Eye Res 2004; 78: 379-88.
27. Kidron H, Vellonen KS, del Amo EM, Tissari A, Urtti A. Prediction of the corneal permeability of drug-like compounds. Pharm Res 2010; 27: 1398-407.
28. Bucolo C, Drago F, Salomone S. Ocular drug delivery: a clue from nanotechnology. Front Pharmacol 2012; 3: 188.
29. Leonardi A, Bucolo C, Drago F, Salomone S, Pignatello R. Cationic solid lipid nanoparticles enhance ocular hypotensive effect of melatonin in rabbit. Int J Pharm 2014; 478: 180-6.
30. Wong TT, Novack GD, Natarajan JV, Ho CL, Htoon HM, Venkatraman SS. Nanomedicine for glaucoma: sustained release latanoprost offers a new therapeutic option with substantial benefits over eyedrops. Drug Deliv Transl Res 2014; 4: 303-9.
31. Kaiserman I, Fendyur A, Vinker S. Topical beta blockers in asthmatic patients-is it safe? Curr Eye Res 2009; 34: 517-22.
32. Martinez T, Gonzalez MV, Roehl I, Wright N, Paneda C, Jimenez AI. In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. Mol Ther: the journal of the American Society of Gene Therapy 2014; 22: 81-91.
33. Moreno-Montanes J, Sadaba B, Ruz V, et al. Phase I clinical trial of SYL040012, a small interfering RNA targeting beta-adrenergic receptor 2, for lowering intraocular pressure. Mol Ther 2014; 22: 226-32.
34. Alarma-Estrany P, Pintor J. Melatonin receptors in the eye: location, second messengers and role in ocular physiology. Pharmacol Therap 2007; 113: 507-22.
35. Wiechmann AF, Summers JA. Circadian rhythms in the eye: the physiological significance of melatonin receptors in ocular tissues. Prog Retinal Eye Res 2008; 27: 137-60.
36. Agorastos A, Huber CG. The role of melatonin in glaucoma: implications concerning pathophysiological relevance and therapeutic potential. J Pineal Res 2011; 50: 1-7.
37. Alarma-Estrany P, Guzman-Aranguez A, Huete F, et al. Design of novel melatonin analogs for the reduction of intraocular pressure in normotensive rabbits. J Pharmacol Exp Therap 2011; 337: 703-9.
38. Crooke A, Colligris B, Pintor J. Update in glaucoma medicinal chemistry: emerging evidence for the importance of melatonin analogues. Curr Med Chem 2012; 19: 3508-22.
39. Alcantara-Contreras S, Baba K, Tosini G. Removal of melatonin receptor type 1 increases intraocular pressure and retinal ganglion cells death in the mouse. Neurosci Lett 2011; 494: 61-4.
40. Crooke A, Huete-Toral F, Martinez-Aguila A, Martin-Gil A, Pintor J. Melatonin and its analog 5-methoxycarbonylamino-Nacetyltryptamine potentiate adrenergic receptor-mediated ocular hypotensive effects in rabbits: significance for combination therapy in glaucoma. J Pharmacol Exp Therap 2013; 346: 138-45.
41. Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev 2005; 9: 11-24.
42. Zlotos DP, Jockers R, Cecon E, Rivara S, Witt-Enderby PA. MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem 2014; 57: 3161-85.
43. Quinteros D, Vicario-de-la-Torre M, Andres-Guerrero V, et al. Hybrid formulations of liposomes and bioadhesive polymers improve the hypotensive effect of the melatonin analogue 5-MCANAT in rabbit eyes. PLoS One 2014; 9: e110344.
44. Musumeci T, Bucolo C, Carbone C, Pignatello R, Drago F, Puglisi G. Polymeric nanoparticles augment the ocular hypotensive effect of melatonin in rabbits. Int J Pharm 2013; 440: 135-40.
45. Rauz S, Cheung CM, Wood PJ, et al. Inhibition of 11betahydroxysteroid dehydrogenase type 1 lowers intraocular pressure in patients with ocular hypertension. QJM: monthly J Assoc Phys 2003; 96: 481-90.
46. Schwartz B, McCarty G, Rosner B. Increased plasma free cortisol in ocular hypertension and open angle glaucoma. Arch Ophthalmol 1987; 105: 1060-5.
47. Anderson S, Carreiro S, Quenzer T, et al. In vivo evaluation of 11beta-hydroxysteroid dehydrogenase activity in the rabbit eye. J Ocul Pharmacol Therap 2009; 25: 215-22.
48. Scott JS, Goldberg FW, Turnbull AV. Medicinal chemistry of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta- HSD1). J Med Chem 2014; 57: 4466-86.
49. Woodward DF, Liang Y, Krauss AH. Prostamides (prostaglandinethanolamides) and their pharmacology. Br J Pharmacol 2008; 153: 410-9.
50. Schachar RA, Raber S, Courtney R, Zhang M. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr Eye Res 2011; 36: 809-17.
51. Prasanna G, Carreiro S, Anderson S, et al. Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma. Exp Eye Res 2011; 93: 256-64.
52. Yanochko GM, Affolter T, Eighmy JJ, et al. Investigation of ocular events associated with taprenepag isopropyl, a topical EP2 agonist in development for treatment of glaucoma. J Ocul Pharmacol Therap 2014; 30: 429-39.
53. Boussommier-Calleja A, Bertrand J, Woodward DF, Ethier CR, Stamer WD, Overby DR. Pharmacologic manipulation of conventional outflow facility in ex vivo mouse eyes. Investigative Ophthalmol Visual Sci 2012; 53: 5838-45.
54. Weinreb RN, Ong T, Scassellati Sforzolini B, Vittitow JL, Singh K, Kaufman PL. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol 2015; 99: 738-45.
55. Wiederholt M, Sturm A, Lepple-Wienhues A. Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide. Investigative Ophthalmol Visual Sci 1994; 35: 2515-20.
56. Ellis DZ, Sharif NA, Dismuke WM. Endogenous regulation of human Schlemm's canal cell volume by nitric oxide signaling. Investig Ophthalmol Visual Sci 2010; 51: 5817-24.
57. Stamer WD, Lei Y, Boussommier-Calleja A, Overby DR, Ethier CR. eNOS, a pressure-dependent regulator of intraocular pressure. Investig Ophthalmol Visual Sci 2011; 52: 9438-44.
58. Heyne GW, Kiland JA, Kaufman PL, Gabelt BT. Effect of nitric oxide on anterior segment physiology in monkeys. Investig Ophthalmol Visual Sci 2013; 54: 5103-10.
59. Stagni E, Bucolo C, Motterlini R, Drago F. Morphine-induced ocular hypotension is modulated by nitric oxide and carbon monoxide: role of mu3 receptors. J Ocul Pharmacol Therap 2010; 26: 31- 5.
60. Cavet ME, Vittitow JL, Impagnatiello F, Ongini E, Bastia E. Nitric oxide (NO): an emerging target for the treatment of glaucoma. Investig Ophthalmol Visual Sci 2014; 55: 5005-15.
61. Salomone S, Foresti R, Villari A, Giurdanella G, Drago F, Bucolo C. Regulation of vascular tone in rabbit ophthalmic artery: cross talk of endogenous and exogenous gas mediators. Biochem Pharmacol 2014; 92: 661-8.
62. Li P, Shen TT, Johnstone M, Wang RK. Pulsatile motion of the trabecular meshwork in healthy human subjects quantified by phase-sensitive optical coherence tomography. Biomed Opt Express 2013; 4: 2051-65.
63. Zhang M, Maddala R, Rao PV. Novel molecular insights into RhoA GTPase-induced resistance to aqueous humor outflow through the trabecular meshwork. Am J Physiol Cell Physiol 2008; 295: C1057-70.
64. Wang SK, Chang RT. An emerging treatment option for glaucoma: Rho kinase inhibitors. Clin Ophthalmol 2014; 8: 883-90.
65. Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M. Phase 2 randomized clinical study of a Rho kinase inhibitor, K- 115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 2013; 156: 731-6.
66. Kopczynski C. IOP-lowering efficacy and tolerability of AR- 13324, a dual mechanism kinase inhibitor for the treatment of glaucoma. In: Sci IOV, ARVO annual meeting: Fort Lauderdale, Fla: USA 2012.
67. Sumi K, Inoue Y, Nishio M, et al. IOP-lowering effect of isoquinoline- 5-sulfonamide compounds in ocular normotensive monkeys. Bioorganic Med Chem Lett 2014; 24: 831-4.
68. Harrison BA, Almstead ZY, Burgoon H, et al. Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma. ACS Med Chem Lett 2015; 6: 84-8.
69. Crosson CE, Sloan CF, Yates PW. Modulation of conventional outflow facility by the adenosine A1 agonist N6-cyclohexyladenosine. Investig Ophthalmol Visual Sci 2005; 46: 3795-9.
70. Li A, Banerjee J, Leung CT, Peterson-Yantorno K, Stamer WD, Civan MM. Mechanisms of ATP release, the enabling step in purinergic dynamics. Cell Physiol Biochem 2011; 28: 1135-44.
71. Ghaffarieh A. Evaluation of the neuroprotective effects of trabodenoson in a model of acute ocular hypertension. In: Sci IOV, Ed. ARVO annual meeting 2014: Orlando, Fla. USA 2014.
72. Kaufman PL, Rasmussen CA. Advances in glaucoma treatment and management: outflow drugs. Investig Ophthalmol Visual Sci 2012; 53: 2495-500.
73. Wang Z, Do CW, Avila MY, et al. Nucleoside-derived antagonists to A3 adenosine receptors lower mouse intraocular pressure and act across species. Exp Eye Res 2010; 90: 146-54.
74. Petrelli R, Torquati I, Kachler S, et al. 5'-C-ethyl-tetrazolyl-N(6)- substituted adenosine and 2-chloro-adenosine derivatives as highly potent dual acting A1 adenosine receptor agonists and A3 adenosine receptor antagonists. J Med Chem 2015; 58: 2560-6.
75. Hepler RS, Frank IR. Marihuana smoking and intraocular pressure. JAMA 1971; 217: 1392.
76. Merritt JC, Crawford WJ, Alexander PC, Anduze AL, Gelbart SS. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology 1980; 87: 222-8.
77. Zhong L, Geng L, Njie Y, Feng W, Song ZH. CB2 cannabinoid receptors in trabecular meshwork cells mediate JWH015-induced enhancement of aqueous humor outflow facility. Investig Ophthalmol Visual Sci 2005; 46: 1988-92.
78. McIntosh BT, Hudson B, Yegorova S, Jollimore CA, Kelly ME. Agonist-dependent cannabinoid receptor signalling in human trabecular meshwork cells. Br J Pharmacol 2007; 152: 1111-20.
79. Wan Z, Woodward DF, Stamer WD. Endogenous bioactive lipids and the regulation of conventional outflow facility. Exp Rev Ophthalmol 2008; 3: 457-70.
80. Njie YF, Kumar A, Qiao Z, Zhong L, Song ZH. Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility. Investig Ophthalmol Visual Sci 2006; 47: 1999-2005.
81. Kumar A, Song ZH. CB1 cannabinoid receptor-mediated changes of trabecular meshwork cellular properties. Mol Vis 2006; 12: 290- 7.
82. Oltmanns MH, Samudre SS, Castillo IG, et al. Topical WIN55212- 2 alleviates intraocular hypertension in rats through a CB1 receptor mediated mechanism of action. J Ocul Pharmacol Therap 2008; 24: 104-15.
83. Chen J, Runyan SA, Robinson MR. Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol 2011; 5: 667-77.
84. Gagliano C, Ortisi E, Pulvirenti L, et al. Ocular hypotensive effect of oral palmitoyl-ethanolamide: a clinical trial. Investig Ophthalmol Visual Sci 2011; 52: 6096-100.
85. Kumar A, Qiao Z, Kumar P, Song ZH. Effects of palmitoylethanolamide on aqueous humor outflow. Investig Ophthalmol Visual Sci 2012; 53: 4416-25.
86. Mainolfi N, Powers J, Amin J, et al. An effective prodrug strategy to selectively enhance ocular exposure of a cannabinoid receptor (CB1/2) agonist. J Med Chem 2013; 56: 5464-72.
87. Sharif NA, Senchyna M. Serotonin receptor subtype mRNA expression in human ocular tissues, determined by RT-PCR. Mol Vis 2006; 12: 1040-7.
88. Sharif NA, McLaughlin MA, Kelly CR, et al. Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. Exp Eye Res 2009; 88: 386-97.
89. Sharif NA. Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action. Curr Drug Targets 2010; 11: 978-93.
90. Tekat D, Guler C, Arici M, Topalkara A, Erdogan H. Effect of ketanserin administration on intraocular pressure. Ophthalmologica. Journal international d'ophtalmologie. Int J Ophthalmol Zeitschrift fur Augenheilkunde 2001; 215: 419-23.
91. Chu E, Chu TC, Potter DE. Mechanisms and sites of ocular action of 7-hydroxy-2-dipropylaminotetralin: a dopamine(3) receptor agonist. J Pharmacol Exp Therap 2000; 293: 710-6.
92. Bucolo C, Leggio GM, Maltese A, Castorina A, D'Agata V, Drago F. Dopamine-(3) receptor modulates intraocular pressure: implications for glaucoma. Biochem Pharmacol 2012; 83: 680-6.
93. Platania CB, Leggio GM, Drago F, Salomone S, Bucolo C. Regulation of intraocular pressure in mice: structural analysis of dopaminergic and serotonergic systems in response to cabergoline. Biochem Pharmacol 2013; 86: 1347-56.
94. NIHR HSC. What's coming in Glaucoma 2013.
95. Aung T, Laganovska G, Paredes HTJ, Branch JD, Tsorbatzoglou A, Goldberg I. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension. Ophthalmology 2014; 121: 2348-55.
96. Clineschmidt CM, Williams RD, Snyder E, Adamsons IA. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group. Ophthalmology 1998; 105: 1952-9.
97. Ohguro I, Ohguro H. The effects of a fixed combination of 0.5% timolol and 1% dorzolamide on optic nerve head blood circulation. J Ocul Pharmacol Therap 2012; 28: 392-6.
98. Woodward DF, Wang JW, Poloso NJ Recent progress in prostaglandin F2α ethanolamide (prostamide F2α) research and therapeutics. Pharmacol Rev 2013; 65: 1135-47.
99. Schuman JS, Horwitz B, Choplin NT, David R, Albracht D, Chen K. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol 1997; 115: 847-52.
100. Spiga MG, Borras T. Development of a gene therapy virus with a glucocorticoid-inducible MMP1 for the treatment of steroid glaucoma. Investig Ophthalmol Visual Sci 2010; 51: 3029-41.